Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03483961 · ClinicalTrials.gov registry record · Phase 2
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
A Phase 2 study of Chikungunya Virus Infection, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 2
- Development phase
- 445
- Enrollment target
- 3
- Study locations
NCT03483961 is a Phase 2 study of Chikungunya Virus Infection that has completed, run by Bavarian Nordic. The registered enrollment target is 445 participants, above the 346-participant average among 4 other Chikungunya Virus Infection trials with a reported enrollment target (29% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT03483961, a Phase 2 study of Chikungunya Virus Infection, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 445 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this Phase 2 trial is to evaluate the immune response to and safety profile of various doses/formulations/and schedules of administration of PXVX0317 in healthy adults. Primary Objective: To assess the immune response to the vaccine Secondary Objectives: To assess the kinetics of the immune response to different doses/formulations/schedules To assess the persistence of immune responses to different doses/formulations/schedules To assess the effect of a booster dose of the vaccine Safety Objective: To assess local and systemic reactions to the vaccine and to describe the safety profile of the vaccine
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CHIKV VLP/unadjuvanted
- BIOLOGICAL CHIKV VLP/adjuvanted
Study Locations (3)
Kansas
- Johnson County Clin-Trials - Lenexa
Missouri
- The Center for Pharmaceutical Research - Kansas City
Utah
- Advanced Clinical Research - West Jordan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 445 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2020-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03483961
The ClinicalTrials.gov registry entry for NCT03483961 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 445 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 346-participant average among 4 other Chikungunya Virus Infection trials with a reported enrollment target (29% higher). The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chikungunya Virus Infection appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03483961 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Kansas, Missouri, Utah.
Frequently Asked Questions
What is clinical trial NCT03483961 about?
NCT03483961 is a clinical study titled "Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults". The goal of this Phase 2 trial is to evaluate the immune response to and safety profile of various doses/formulations/and schedules of administration of PXVX0317 in healthy adults. Primary Objective: To assess the immune response to the vaccine Secondary Objectives: To assess the kinetics of the...
What is the current status of trial NCT03483961?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 445 participants. The study started on 2018-04-18. Estimated completion is 2020-09-21.
What conditions does trial NCT03483961 study?
This clinical trial studies the following conditions: Chikungunya Virus Infection.
What interventions are being tested in trial NCT03483961?
The interventions under investigation include: Placebo (BIOLOGICAL), CHIKV VLP/unadjuvanted (BIOLOGICAL), CHIKV VLP/adjuvanted (BIOLOGICAL).
Who is sponsoring clinical trial NCT03483961?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03483961 being conducted?
This trial has 3 study locations across Kansas, Missouri, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chikungunya Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
ACTIVE NOT RECRUITING · Phase 3
-
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
ACTIVE NOT RECRUITING · Phase 3
-
Phase 1 Study of SAR440894 vs Placebo
COMPLETED · Phase 1
-
Phase I Trial of Measles Vectored Chikungungya Vaccine
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.